Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -111.46% is 68% above its 5-year average of -352.36%, near the high end of its 5-year range (-848.64%–-49.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 50.81% above its 12-month average of -226.58%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -111.46%.
RETURN ON EQUITY (ROE)
-111.46%
RETURN ON EQUITY (ROE) AVG TTM
-226.58%
RETURN ON EQUITY (ROE) AVG 3Y
-371.45%
RETURN ON EQUITY (ROE) AVG 5Y
-352.36%
RETURN ON EQUITY (ROE) AVG 10Y
-211.25%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+50.81%
CURRENT VS 3Y AVG
+69.99%
CURRENT VS 5Y AVG
+68.37%
CURRENT VS 10Y AVG
+47.24%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 535 covered companies
CURRENT VS SECTOR MEDIAN
-177.25%
vs the sector median at left
KALA BIO, Inc.
Market Cap
$7.22M
Return on Equity (ROE)
-111.46%
TTM Avg
-226.58%
3Y Avg
-371.45%
5Y Avg
-352.36%
Market Cap
$7.28M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$7.42M
Return on Equity (ROE)
-225.67%
TTM Avg
-236.53%
3Y Avg
-220.64%
5Y Avg
-186.37%
Market Cap
$7.31M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$7.20M
Return on Equity (ROE)
-120.58%
TTM Avg
-99.12%
3Y Avg
-428.18%
5Y Avg
-321.37%
Market Cap
$7.09M
Return on Equity (ROE)
N/A
TTM Avg
158.93%
3Y Avg
168.21%
5Y Avg
33.14%
Market Cap
$6.94M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$7.83M
Return on Equity (ROE)
-91.75%
TTM Avg
-295.51%
3Y Avg
-88.38%
5Y Avg
-106.70%
Market Cap
$6.78M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.22M | -111.46% | -226.58% | -371.45% | -352.36% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.28M | -218.65% | -54.74% | -35.36% | -35.36% |
| Longeveron Inc. (LGVN)vs › | $7.42M | -225.67% | -236.53% | -220.64% | -186.37% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | -120.58% | -99.12% | -428.18% | -321.37% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.09M | N/A | 158.93% | 168.21% | 33.14% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | -370.16% | -148.31% | -87.53% | -43.20% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | -91.75% | -295.51% | -88.38% | -106.70% |
| Aclarion, Inc. (ACON)vs › | $6.78M | -54.09% | -388.62% | -105.04% | -44.72% |
| HeartSciences Inc. (HSCS)vs › | $7.86M | N/A | -2138.11% | -1780.63% | -1152.40% |
ROE
-111.5%
ROA
-95.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -111.46% |
| 2026-03-31 | -182.64% |
| 2025-12-31 | -385.65% |
| 2025-03-31 | -624.58% |
| 2024-12-31 | -312.29% |
| 2024-09-30 | -568.06% |
| 2024-06-30 | -282.26% |
| 2024-03-31 | -593.77% |
| 2023-12-31 | -562.35% |
| 2023-09-30 | -413.57% |
| 2023-06-30 | -49.38% |
| 2023-03-31 | -112.25% |
| 2022-12-31 | -236.23% |
| 2021-12-31 | -848.64% |
| 2021-09-30 | -205.22% |
| 2021-06-30 | -149.48% |
| 2021-03-31 | -102.73% |
| 2020-12-31 | -104.33% |
| 2020-09-30 | -89.76% |
| 2020-06-30 | -70.11% |
| 2020-03-31 | -64.25% |
| 2019-12-31 | -317.75% |
| 2019-09-30 | -226.70% |
| 2019-06-30 | -147.44% |
| 2019-03-31 | -98.13% |
| 2018-12-31 | -63.57% |
| 2018-09-30 | -96.13% |
| 2018-06-30 | -69.58% |
| 2018-03-31 | -54.50% |
| 2017-12-31 | -47.07% |
| 2017-09-30 | -39.77% |
| 2017-03-31 | -167.69% |
